ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 191 filers reported holding ASCENDIS PHARMA A/S in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,205,857 | +66.3% | 13,511 | +99.8% | 0.06% | +107.1% |
| Q1 2023 | $725,022 | +27.2% | 6,762 | +44.9% | 0.03% | +33.3% |
| Q4 2022 | $569,981 | +127.1% | 4,667 | +91.7% | 0.02% | +133.3% |
| Q3 2022 | $251,000 | +20.7% | 2,435 | +8.7% | 0.01% | +50.0% |
| Q2 2022 | $208,000 | -88.3% | 2,241 | -83.0% | 0.01% | -91.3% |
| Q4 2021 | $1,771,000 | -25.9% | 13,165 | -29.0% | 0.07% | -6.8% |
| Q1 2021 | $2,390,000 | – | 18,547 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |